Skip to main content

Table 2 Pooled analysis and stratified analyses of SSc patients and healthy controls for rs10744676 genetic variant, located in the KCNA5 gene

From: KCNA5 gene is not confirmed as a systemic sclerosis-related pulmonary arterial hypertension genetic susceptibility factor

  Genotype, n(%)   Allele test
Subgroup (n) C/C C/T T/T MAF (%) P MH OR (95% CI) P BD
Controls (n = 2,690) 37 (1.38) 597 (22.19) 2,056 (76.43) 12.47    
SSc (n = 2,343) 43 (1.84) 471 (20.10) 1,829 (78.06) 11.89 0.49 0.96 (0.85-1.08) 0.53
lcSSc (n = 1,642) 31 (1.89) 327 (19.91) 1,284 (78.20) 11.85 0.48 0.95 (0.83-1.09) 0.63
dcSSc (n = 701) 12 (1.71) 144 (20.54) 545 (77.75) 11.98 0.80 0.98 (0.81-1.17) 0.59
ACA+ (n = 931) 18 (1.93) 197 (21.16) 716 (76.91) 12.51 0.49 1.06 (0.90-1.24) 0.96
ATA+ (n = 568) 8 (1.41) 117 (20.60) 443 (77.99) 11.71 0.85 0.98 (0.80-1.20) 0.94
Fib+ (n = 771) 14 (1.82) 154 (19.97) 603 (78.21) 11.80 0.34 0.92 (0.77-1.09) 0.92
PAH+ (n = 179) 2 (1.12) 37 (20.67) 140 (78.21) 11.45 0.44 0.88 (0.63-1.23) 0.70
  1. MAF, minor allele frequency; PMH, Mantel-Haenszel test under fixed-effect P values. Controls are used as reference for all comparisons, and P values have been calculated for the allelic model. OR, odds ratio for the minor allele; 95% CI, 95% confidence interval; SSc, systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; dcSSc, diffuse cutaneous systemic sclerosis; ACA+, anti-centromere autoantibody-positive patient; ATA+, anti-topoisomerase autoantibody-positive patient; Fib+, lung fibrosis-positive patient (HRCT); PAH+, pulmonary arterial hypertension-positive patients (right-heart catheterization).